Disease · MONDO_0019436
psoriasis-related juvenile idiopathic arthritis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. psoriasis-related juvenile idiopathic arthritis. Diseases, record MONDO_0019436. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019436
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GUSELKUMAB | CHEMBL2364648 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SECUKINUMAB | CHEMBL1743068 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| USTEKINUMAB | CHEMBL1201835 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ADALIMUMAB | CHEMBL1201580 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| APREMILAST | CHEMBL514800 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BIMEKIZUMAB | CHEMBL4297700 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEUCRAVACITINIB | CHEMBL4435170 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GOLIMUMAB | CHEMBL1201833 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets15
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL12B | Interleukin-12 | 3 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Phase 3 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 3 | Interleukin-23 inhibitor | Phase 3 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| IL17A | Interleukin-17A | 2 | Interleukin 17A inhibitor | Phase 3 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| IL12A | Interleukin-12 | 1 | Interleukin-12 inhibitor | Phase 3 | https://conductscience.org/library/genes/3592 | Drugs and targets |
| IL17F | Interleukin-17F | 1 | Interleukin-17F inhibitor | Phase 3 | https://conductscience.org/library/genes/112744 | Drugs and targets |
1 to 10 of 15
See all 15 targetsTrials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03773978 | A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis | Phase 3 | 220 | 2022-10-07 | Juvenile Idiopathic Arthritis | BARICITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02277444 | A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy | Phase 3 | 130 | 2020-11-18 | Arthritis, Juvenile | GOLIMUMAB, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT03769168 | An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) | Phase 3 | 55 | 2025-05-23 | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02698475 | An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age | Phase 3 | 44 | 2020-08-28 | Psoriasis | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06663332 | A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants | Phase 3 | 196 | Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04804553 | Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis | Phase 3 | 60 | Active Juvenile Psoriatic Arthritis | APREMILAST | Its record names the disease | ClinicalTrials.gov | |
| NCT06869551 | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis | Phase 3 | 60 | Juvenile Psoriatic Arthritis | DEUCRAVACITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05083182 | A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis | Phase 3 | 48 | Arthritis, Juvenile | GUSELKUMAB, USTEKINUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06100744 | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | Phase 3 | 40 | Juvenile Psoriatic Arthritis | ADALIMUMAB, RISANKIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06668181 | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | Phase 3 | 40 | Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis | BIMEKIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ustekinumab Standard Dosage (Main Study) vs Ustekinumab Standard Dosage (Long-Term Extension [LTE]): deaths from any cause | 0 of 44 | 0 of 28 | 72 | NCT02698475 | Trial comparisons |
| Ustekinumab Standard Dosage (Main Study) vs Ustekinumab Standard Dosage (Long-Term Extension [LTE]): serious adverse events | 3 of 44 | 1 of 28 | 72 | NCT02698475 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019436
GET https://conductscience.org/api/diseases/v1/MONDO_0019436/drugs